Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Abemaciclib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Warfarin
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 28 Mar 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Feb 2018.